Furthermore, 5-ASA, a PPARγ agonist and widely used as a first-line medication for the treatment of ulcerative colitis [27], has been shown to increase the spare mitochondrial respiratory capacity in Caco-2 cells, indicative of increased mitochondrial bioenergetics [14]. The gene discussed is PPARG; the disease is ulcerative colitis.